Cyclacel Pharma Reports Data From Phase 2 Sapacitabine Trial - Quick Facts

(RTTNews) - Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) announced new, primary endpoint data from an ongoing, open-label, multicenter, randomized Phase 2 trial of oral sapacitabine capsules, the company's lead product candidate, in older patients with myelodysplastic syndromes after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine. The investigators for the study said the survival data continue to be impressive and justify further clinical evaluation of sapacitabine.

The data showed that the 7-day dose regimen of 200 mg twice daily appears to be a better schedule with a one-year survival rate of 38%, median overall survival of approximately 10 months and response rate of 19%. The 30-day mortality from all causes for all patients is 5%.